Comparative effectiveness of different angiotensin-converting enzyme inhibitors on the risk of hospitalization in patients with heart failure

Journal of Comparative Effectiveness Research

Volumn 1, Issue 2, 2012, Pages 195-206

  Chitnis, Abhishek S ^a   Aparasu, Rajender R ^a   Chen, Hua ^a   Johnson, Michael L ^b  

^a UNIVERSITY OF HOUSTON   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

angiotensin converting enzyme inhibitors; comparative effectiveness; heart failure; multiple propensity scores

Indexed keywords

CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FOSINOPRIL; LISINOPRIL;

AGED; ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG USE; FEMALE; HEALTH CARE QUALITY; HEART FAILURE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; PATIENT SAFETY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT;

EID: 84886943593     PISSN: 20426305     EISSN: 20426313     Source Type: Journal    
DOI: 10.2217/cer.12.5     Document Type: Article

References (47)

1. Hunt SA, Abraham WT, Chin MH et al. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration with the International Society for Heart and Lung Transplantation. J. Am. Coll. Cardiol. 53(15), e1-e90 (2009).
2. Trewet CB, Shireman TI, Rigler SK, Howard PA. Do ACE inhibitors/ angiotensin II type 1 receptor antagonists reduce hospitalisations in older patients with heart failure? A propensity analysis. Drugs Aging 24(11), 945-955 (2007).
3. Koelling TM, Chen RS, Lubwama RN, L'Italien GJ, Eagle KA. The expanding national burden of heart failure in the United States: the influence of heart failure in women. Am. Heart J. 147(1), 74-78 (2004).
4. Lloyd-Jones D, Adams R, Carnethon M et al. Heart disease and stroke statistics - 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 119(3), 480-486 (2009).
5. Consensus recommendations for the management of chronic heart failure. On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure. Am. J. Cardiol. 83, 1A-38A (1999).
6. Pfeffer MA, Braunwald E, Moye LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N. Engl. J. Med. 327(10), 669-677 (1992).
7. Kober L, Torp-Pedersen C, Carlsen JE et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N. Engl. J. Med. 333, 1670-1676 (1992).
8. Cohn JN, Johnson G, Ziesche S et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N. Engl. J. Med. 325(5), 303-310 (1991).
9. Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin- converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N. Engl. J. Med. 332, 80-85 (1995).
10. No authors listed. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 342, 821-828 (1993).
11. No authors listed. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N. Engl. J. Med. 316, 1429-1435 (1987).
12. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N. Engl. J. Med. 325, 293-302 (1991).
13. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 273, 1450-1456 (1995).
14. Flather MD, Yusuf S, Kober L et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 355(9215), 1575-1581 (2000).
15. Gambassi G, Lapane KL, Sgadari A et al. Effects of angiotensin-converting enzyme inhibitors and digoxin on health outcomes of very old patients with heart failure. SAGE Study Group. Systematic Assessment of Geriatric drug use via Epidemiology. Arch. Intern. Med. 160(1), 53-60 (2000).
16. Buch P, Rasmussen S, Abildstrom SZ, Kober L, Carlsen J, Torp-Pedersen C. The long-term impact of the angiotensin-converting enzyme inhibitor trandolapril on mortality and hospital admissions in patients with left ventricular dysfunction after a myocardial infarction: follow-up to 12 years. Eur. Heart J. 26(2), 145-152 (2005).
17. Ahmed A, Kiefe CI, Allman RM, Sims RV, DeLong JF. Survival benefits of angiotensin-converting enzyme inhibitors in older heart failure patients with perceived contraindications. J. Am. Geriatr. Soc. 50(10), 1659-1666 (2002).
18. Brown NJ, Vaughan DE. Angiotensin-converting enzyme inhibitors. Circulation 97, 1411-1420 (1998).
19. Chitnis AS, Aparasu RR, Chen H, Johnson ML. Effect of certain angiotensin-converting enzyme inhibitors on mortality in heart failure: a multiple propensity analysis. Res. Social Adm. Pharm. doi:10.1016/j.sapharm. 2011.03.001 (2011) (Epub ahead of print).
20. Shah BR, Laupacis A, Hux JE, Austin PC. Propensity score methods gave similar results to traditional regression modeling in observational studies: a systematic review. J. Clin. Epidemiol. 58(6), 550-559 (2005).
21. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann. Intern. Med. 127(8), 757-763 (1997).
22. Imbens GW. The role of the propensity score in estimating dose-response functions. Biometrika 87(3), 706-710 (2000).
23. Lechner M. Identification and estimation of causal effects of multiple treatments under the conditional independence assumption. In: Econometric Evaluation of Labour Market Policies. Lechner M, Pfeiffer F (Eds). Physica, Springer, Heidelberg, Germany, 43-58 (2001).
24. Joffe M, Rosenbaum P. Invited commentary: propensity scores. Am. J. Epidemiol. 150(4), 327-333 (1999).
25. Lu B, Zanutto E, Hornik R, Rosenbaum PR. Matching with doses in an observational study of a media campaign against drug abuse. J. Am. Stat. Assoc. 96, 1245-1253 (2001).
26. Spreeuwenberg MD, Bartak A, Croon MA et al. The multiple propensity score as control for bias in the comparison of more than two treatment arms: an introduction from a case study in mental health. Med. Care. 48(2), 166-174 (2010).
27. McCullough PA, Philbin EF, Spertus JA, Kaatz S, Sandberg KR, Weaver WD. Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. J. Am. Coll. Cardiol. 39(1), 60-69 (2002).
28. Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr. Med. Res. Opin. 25(9), 2303-2310 (2009).
29. Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol. Drug Saf. 15(8), 565-574 (2006).
30. Deswal A, Petersen NJ, Souchek J, Ashton CM, Wray NP. Impact of race on health care utilization and outcomes in veterans with congestive heart failure. J. Am. Coll. Cardiol. 43(5), 778-784 (2004).
31. Hirano K, Imbens G. Estimation of causal effects using propensity score weighting: an application to data on right heart catheterization. Health Serv. Outcomes Res. Methodol. 2, 259-278 (2001).
32. McNiel DE, Binder RL. Effectiveness of a mental health court in reducing criminal recidivism and violence. Am. J. Psychiatry 164(9), 1395-1403 (2007).
33. Tu K, Mamdani M, Kopp A, Lee D. Comparison of angiotensin-converting enzyme inhibitors in the treatment of congestive heart failure. Am. J. Cardiol. 95(2), 283-286 (2005).
34. Sica DA. The Heart Outcomes Prevention Evaluation study: angiotensin-converting enzyme inhibitors: are their benefits a class effect or do individual agents differ? Curr. Opin. Nephrol. Hypertens. 10(5), 597-601 (2001).
35. Tsikouris JP, Suarez JA, Meyerrose GE, Ziska M, Fike D, Smith J. Questioning a class effect: does ACE inhibitor tissue penetration influence the degree of fibrinolytic balance alteration following an acute myocardial infarction? J. Clin. Pharmacol. 44(2), 150-157 (2004).
36. Abarca J, Malone DC, Armstrong EP, Zachry WM 3rd. Angiotensin-converting enzyme inhibitor therapy in patients with heart failure enrolled in a managed care organization: effect on costs and probability of hospitalization. Pharmacotherapy 24(3), 351-7 (2004).
37. Sin DD, McAlister FA. The effects of beta-blockers on morbidity and mortality in a population-based cohort of 11,942 elderly patients with heart failure. Am. J. Med. 113(8), 650-656 (2002).
38. Johnson ML, Bush RL, Collins TC et al. Propensity score analysis in observational studies: outcomes after abdominal aortic aneurysm repair. Am. J. Surg. 192(3), 336-343 (2006).
39. Pilote L, Abrahamowicz M, Eisenberg M, Humphries K, Behlouli H, Tu JV. Effect of different angiotensin-converting-enzyme inhibitors on mortality among elderly patients with congestive heart failure. CMAJ 178(10), 1303-1311 (2008).
40. Ashton CM, Petersen NJ, Souchek J et al. Geographic variations in utilization rates in Veterans Affairs hospitals and clinics. N. Engl. J. Med. 340(1), 32-39 (1999).
41. Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. J. Am. Coll. Cardiol. 43(3), 317-327 (2004).
42. Philbin EF, Rocco TA Jr, Lindenmuth NW, Ulrich K, Jenkins PL. Systolic versus diastolic heart failure in community practice: clinical features, outcomes, and the use of angiotensin-converting enzyme inhibitors. Am. J. Med. 109(8), 605-613 (2000).
43. Lau HS, de Boer A, Beuning KS, Porsius A. Validation of pharmacy records in drug exposure assessment. J. Clin. Epidemiol. 50(5), 619-625 (1997).
44. Packer M, Poole-Wilson PA, Armstrong PW et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 100(23), 2312-2318 (1999).
45. Konstam MA, Neaton JD, Dickstein K et al. Effects of high-dose versus low dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 374(9704), 1840-1848 (2009).
46. Levine TB, Levine AB, Keteyian SJ, Narins B. The impact of beta-receptor blocker addition to high-dose angiotensin-converting enzyme inhibitor-nitrate therapy in heart failure. Clin. Cardiol. 21(12), 899-904 (1998).
47. Levine AB, Muller C, Levine TB. Effects of high-dose lisinopril- isosorbide dinitrate on severe mitral regurgitation and heart failure remodeling. Am. J. Cardiol. 82(10), 1299-1301 (1998).